The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults

Inclusion Criteria: 1. Patients fully understand this study, voluntarily participate and sign an informed consent form (ICF); 2. Age: 18-75 years old (including boundary values of 18 and 75); 3. Clinically diagnosed adult Mixed Phenotype Acute Leukemia (WHO 2016 criteria) patients with CD19 positivity Exclusion Criteria: The subject's previous history of anti-tumor treatment meets one of the following conditions: 1. Individuals who have previously received bevacizumab 2. Individuals who have received CAR-T therapy or other gene modified cell therapies prior to screening; 3. Within 5 half lives of the first use of the investigational drug, having received anti-tumor treatment including surgery, chemotherapy, targeted therapy, or participating in other clinical trials and receiving clinical trial medication;